Immuneering Corp — Director's Dealing 2022

Jun 23, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2022-06-21

Reporting Person: HAUSMAN DIANA (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-21	Stock Option	$4.63	A	6185	Acquired	2032-06-20	Class A Common Stock (6185)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 21, 2022, and will be fully vested and exercisable on June 21, 2023, or the date of the 2023 annual meeting of stockholders, whichever comes first.